Literature DB >> 32640386

Frequency and antimicrobial susceptibility of bacteria causing bloodstream infections in pediatric patients from United States (US) medical centers (2014-2018): therapeutic options for multidrug-resistant bacteria.

Helio S Sader1, Mariana Castanheira2, Jennifer M Streit2, Cecilia G Carvalhaes2, Rodrigo E Mendes2.   

Abstract

Studies evaluating large series of pediatric patients with bloodstream infections (BSIs) are scarce. We evaluated the frequency and antimicrobial susceptibility of organisms isolated from pediatric patients with BSI and therapeutic options for BSI caused by multidrug-resistant (MDR) organisms. A total of 2423 organisms were consecutively collected from 33 US medical centers between 2014 and 2018, and susceptibility was tested by reference broth microdilution methods. Isolates with an extended-spectrum β-lactamase phenotype were screened for β-lactamase genes. Overall, 40.2% of organisms were Gram-negative bacteria, 57.0% Gram-positives, and 2.8% Candida spp. The 5 most common organisms were Staphylococcus aureus (26.0%), Escherichia coli (13.0%), coagulase-negative staphylococci (8.3%), Enterococcus faecalis (7.1%), and Klebsiella pneumoniae (6.9%). Among S. aureus, 26.0% were oxacillin-resistant and 99.8% were susceptible to ceftaroline (MIC50/90, 0.25/0.5 mg/L). Enterobacterales and Pseudomonas aeruginosa isolates combined represented >85% of Gram-negative bacteria, and all isolates (100.0%) were susceptible to ceftazidime-avibactam.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bacteremia; ESBL; Gram-negative infections; Klebsiella pneumoniae; Pseudomonas aeruginosa

Mesh:

Substances:

Year:  2020        PMID: 32640386     DOI: 10.1016/j.diagmicrobio.2020.115108

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  3 in total

1.  Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and Older.

Authors:  Richard C Franzese; Lynn McFadyen; Kenny J Watson; Todd Riccobene; Timothy J Carrothers; Manoli Vourvahis; Phylinda L S Chan; Susan Raber; John S Bradley; Mark Lovern
Journal:  Clin Pharmacol Ther       Date:  2021-11-22       Impact factor: 6.903

2.  Antibiotic Use Among Hospitalized Children and Neonates in China: Results From Quarterly Point Prevalence Surveys in 2019.

Authors:  Chu-Ning Wang; Jianning Tong; Bin Yi; Benedikt D Huttner; Yibing Cheng; Shuangjie Li; Chaomin Wan; Qingxiong Zhu; Qionghua Zhou; Shiyong Zhao; Zhiqiang Zhuo; Daobin Wang; Chunmei Jia; Qing-Wen Shan; Yun Zhao; Chenfu Lan; Dongchi Zhao; Yibo Zhou; Jing Liu; Chunhui Zhu; Yu Zhu; Rui Li; Xiaodan Wu; Zhenghong Qi; Caihong Wang; Huiling Gao; Wenyu Ye; Liling Zhang; Xiaohong Xu; Hui Hu; Pu Yang; Nicola Magrini; Mei Zeng
Journal:  Front Pharmacol       Date:  2021-03-29       Impact factor: 5.810

3.  Trends of Antimicrobial Susceptibility in Clinically Significant Coagulase-Negative Staphylococci Isolated from Cerebrospinal Fluid Cultures in Neurosurgical Adults: a Nine-Year Analysis.

Authors:  Yi Ye; Ye Tian; Yueyue Kong; Jiawei Ma; Guangzhi Shi
Journal:  Microbiol Spectr       Date:  2022-02-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.